Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Plans For Public Offerings, Emcure, Intas Set To Join Big League Of Indian Pharma

This article was originally published in PharmAsia News

Executive Summary

Experts believe Emcure and Intas may be able to withstand the vagaries of India’s choppy financial market, having developed strong pedigrees of products and consistently growing their businesses.

You may also be interested in...



With Emerging Markets On Radar, AstraZeneca Close To Teaming Up With India's Intas For Sourcing Sterile And Oncology Drugs

MUMBAI - AstraZeneca is days away from signing an agreement with India's Intas Pharmaceuticals for supplies of a large number of generic sterile and oncology products to be sold in emerging markets. The deal will likely cover as many as 45 products to be sold in nine markets, with the scope for expanding the range of products further

After Launching First Pegylated GCSF, Intas Biopharma Examines Technology For Pegylated Erythropoietin

MUMBAI - Ahmedabad, India-based biotech firm Intas Biopharma is looking at commencing research on a generic form of pegylated erythropoietin

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel